Infection with human adenoviruses (ADV) can cause lifethreatening infections in pts after allo-SCT and represents a major reason for transplant related mortality (TRM, in historical cohorts after haplo-SCT up to 30%). Graft manipulation by T-cell depletion affect immune reconstitution and can extend duration of impairment of immunity after SCT. Delayed reconstitution of immunity increases the risk for viral infections. New preparative regimens such as reduced intensity conditioning (RIC) followed by CD3/19 depleted PBSC transplant (3/19depl-PBSCT) try to overcome these limitations. To substantiate this we studied the incidence (inc.) and mortality of ADV infection after ped. allo-SCT overall and as a function of graft. 210 transplants have been performed in 200 ped. pts in Frankfurt between '05 and '11. Donor source was 3/19depl-PBSC (n¼95) and BM (n¼115). Median follow up was 13.9 mths. Weekly post-transpl. ADVscreening was conducted by qPCR in plasma, throats swabs and faeces. Inc. of ADV detection in any compartment at any time-point was 40.0% and sign. higher after 3/19depl-PBSCT compared to BMT; 49.5% vs 32.2% (P ¼ .016). Inc. was 26.7% <¼d60, 20.6% d61 to 100 and 14.0% >d100. Cumulative inc. of 3y TRM (CI 3y TRM) due to ADV disease was 4.6% (3/ 19depl-PBSCT 6.9%, BMT 3.0%; n. sign.). In detail, 14.5% of pts (29/200) died due to non relapse mortality. Amongst these 29 pts, 16 (55.2%) were ADV pos.. ADV positivity was sign. more frequent after 3/19depl-PBSCT compared to BMT (84.6% vs 31.3%; P ¼ .008). Mortality due to ADV disease among TRM pts was 27.6% (3/19depl-PBSCT 38.5%, BMT 18.8%; n. sign.). Overall CI 3y TRM was sign. higher in ADV pos. (n¼84) vs neg. (n¼126) pts (28.7% vs 13.4%, P ¼ .03). Taken together, ADV was detected in every second pt after 3/ 19depl-PBSCT. Although the CI 3y TRM due to ADV disease was low (4.6%), post-transpl. ADV detection sign. increased the risk for subsequent TRM. In summary, ADV represents a severe threat to survival, particularly in pts after 3/19depl-PBSCT. Apparently, more rapid reconstitution of immunity in these pts compared to historical mega-dose CD34 transplants resulted in low mortality due to ADV disease in this high-risk group.
Infection with human adenoviruses (ADV) can cause lifethreatening infections in pts after allo-SCT and represents a major reason for transplant related mortality (TRM, in historical cohorts after haplo-SCT up to 30%). Graft manipulation by T-cell depletion affect immune reconstitution and can extend duration of impairment of immunity after SCT. Delayed reconstitution of immunity increases the risk for viral infections. New preparative regimens such as reduced intensity conditioning (RIC) followed by CD3/19 depleted PBSC transplant (3/19depl-PBSCT) try to overcome these limitations. To substantiate this we studied the incidence (inc.) and mortality of ADV infection after ped. allo-SCT overall and as a function of graft. 210 transplants have been performed in 200 ped. pts in Frankfurt between '05 and '11. Donor source was 3/19depl-PBSC (n¼95) and BM (n¼115). Median follow up was 13.9 mths. Weekly post-transpl. ADVscreening was conducted by qPCR in plasma, throats swabs and faeces. Inc. of ADV detection in any compartment at any time-point was 40.0% and sign. higher after 3/19depl-PBSCT compared to BMT; 49.5% vs 32.2% (P ¼ .016). Inc. was 26.7% <¼d60, 20.6% d61 to 100 and 14.0% >d100. Cumulative inc. of 3y TRM (CI 3y TRM) due to ADV disease was 4.6% (3/ 19depl-PBSCT 6.9%, BMT 3.0%; n. sign.). In detail, 14.5% of pts (29/200) died due to non relapse mortality. Amongst these 29 pts, 16 (55.2%) were ADV pos.. ADV positivity was sign. more frequent after 3/19depl-PBSCT compared to BMT (84.6% vs 31.3%; P ¼ .008). Mortality due to ADV disease among TRM pts was 27.6% (3/19depl-PBSCT 38.5%, BMT 18.8%; n. sign.). Overall CI 3y TRM was sign. higher in ADV pos. (n¼84) vs neg. (n¼126) pts (28.7% vs 13.4%, P ¼ .03). Taken together, ADV was detected in every second pt after 3/ 19depl-PBSCT. Although the CI 3y TRM due to ADV disease was low (4.6%), post-transpl. ADV detection sign. increased the risk for subsequent TRM. In summary, ADV represents a severe threat to survival, particularly in pts after 3/19depl-PBSCT. Apparently, more rapid reconstitution of immunity in these pts compared to historical mega-dose CD34 transplants resulted in low mortality due to ADV disease in this high-risk group. Objective: The goal of this retrospective study was to analyze the clinical outcomes of a large cohort of pediatric and adolescent/young adult (AYA) patients with high-risk acute leukemia (AL) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) with a uniform preparative regimen at Stanford University over the past decade. Patients and Methods: Data was analyzed for 152 pediatric and AYA patients between the ages of 0-21 years who received HSCT for acute leukemia at Stanford University since 2001. This cohort included patients with acute lymphoblastic leukemia (ALL, n¼86), acute myelogenous leukemia (AML; n¼61), and biphenotypic leukemia (n¼5). Both related and unrelated donors were used, including bone marrow, cord blood, and peripheral blood stem cell sources. The majority of patients received FTBI/cyclophosphamide or FTBI/etoposide conditioning. Kaplan-Meier curves were generated to evaluate overall survival (OS)and relapse free survival (RFS) based on era of treatment, diagnosis, donor source, and disease status at time of transplant. Results: Significant improvement in early outcomes at 1 and 3 years was noted for patients who were treated over the last decade regardless of diagnosis or disease status at the time of transplant. One and 5 year overall survival for ALL improved from 57% and 46% prior to 2001 to 92% and 74% since 2006. The best long term survival (69% at 5 years) was observed for ALL in first complete remission (CR1). Five year OS decreased incrementally for patients in CR2 (59%) and CR3+ (34%).
Interestingly 5 year OS in ALL was greater in patients who received an unrelated donor (URD) transplant for ALL (67%) as compared to those who had a sibling donor (51%). Conclusions: The improved outcomes seen in pediatric and AYA patients transplanted for leukemia indicate the beneficial effects of improved supportive care, earlier use of SCT in high risk patients, and improved identification of alternate donors (URD). Importantly, patients with ALL had higher early and long-term overall and relapse-free survival, with better outcomes for patients transplanted in CR1. The data presented demonstrate that HSCT can be beneficial and should be considered, even for patients with advanced disease. The improved overall and relapse free survival in our 
